DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells
Menée sur des cellules souches de gliomes, cette étude met en évidence l'intérêt des inhibiteurs de la réponse aux dommages causés à l'ADN pour augmenter l'efficacité des traitements tumoraux par champs électriques
High-grade gliomas are primary brain cancers with unacceptably low and persistent survival rates of 10–16 months for WHO grade 4 gliomas over the last 40 years, despite surgical resection and DNA-damaging chemo-radiotherapy. More recently, tumour-treating fields therapy (TTFields) has demonstrated modest survival benefit and been clinically approved in several countries. TTFields is thought to mediate anti-cancer activity by primarily disrupting mitosis. However, recent data suggest that TTFields may also attenuate DNA damage repair and replication fork dynamics, providing a potential platform for therapeutic combinations incorporating standard-of-care treatments and targeted DNA damage response inhibitors (DDRi).